4 Results for "

STAT3-IN-12

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "STAT3-IN-12" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-150538
CAS No.: 2980758-31-2
Purity:  99.87%
Target:  

STAT Apoptosis

Research Areas:  

Cancer

STAT3-IN-12 is a potent STAT3 signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145935
CAS No.: 1198078-60-2
Purity:  98.57%
Target:  

Insulin Receptor STAT

Research Areas:  

Cancer

NT219 is a potent and dual inhibitor of insulin receptor substrates 1/2 (IRS1/2) and STAT3. IRS1/2 and STAT3 are major signaling junctions regulated by various oncogenes. NT219 affects IRS1/2 degradation and inhibits STAT3 phosphorylation. NT219 has the potential for the research of cancer diseases .
loading...
    loading...
Cat. No.: HY-P10641
CAS No.: 876460-72-9
Target:  

Exosomes STAT ERK Akt

Research Areas:  

Cardiovascular Disease

Heart-homing peptide is a heart-targeting peptide with the sequence CRPPR that mediates cardiac endothelial targeting and accumulates in cardiac tissues. Heart-homing peptide mediates the translocation of liposomal and exosomal cargos across cardiac endothelium into interstitial tissues, enhances the accumulation of exosomes in the heart, and inhibits the GP130-STAT3/ERK1/2/AKT pathway. Heart-homing peptide accumulates at sites of ischemia/reperfusion, myocardial infarction and hypertrophy in mice. Heart-homing peptide can be used for the research of cardiovascular diseases .
loading...
    loading...
Cat. No.: HY-125542
CAS No.: 2136278-38-9
Purity:  99.73%
Target:  

Apoptosis JAK STAT ERK PI3K Akt

Research Areas:  

Cancer

DCZ3301 is an apoptosis inducer. DCZ3301 modulates JAK2/STAT3, ERK1/2, and PI3K/AKT pathways. DCZ3301 induces G2/M and M phase cell cycle arrest and inhibits cell proliferation and viability. DCZ3301 enhances DNA damage, inhibits DNA repair, and suppresses angiogenesis. DCZ3301 can be used for the research of diffuse large B-cell lymphoma, multiple myeloma and leukemia/lymphoma .
loading...
    loading...